Biomedical Systems Announces Affiliation With the ePRO Consortium
(St. Louis, March 24, 2015) – Biomedical Systems, a premier global provider of centralized diagnostic services, announced its affiliation with the Electronic Patient-Reported Outcome (ePRO) Consortium, a program run by the Critical Path Institute (C-Path).
Biomedical Systems joined the ePRO Consortium on Jan. 1 and will collaborate with the group’s 10 other members to advance the quality, practicality and acceptance of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.
“Clinical outcome assessments are becoming more important in clinical trials to determine whether a drug has demonstrated a treatment benefit,” said Timothy Barrett, chief operating officer at Biomedical Systems. “By joining the ePRO Consortium, Biomedical Systems will contribute in a non-competitive and neutral environment to improve the quality of data collection methods for clinical outcomes assessments.”
With this new partnership, Biomedical Systems reinforces its dedication to the advancement of ePRO to increase the quality of data for electronic data capture. Biomedical Systems’ second generation ePRO platform supports home, site and Web-based systems to collect timely, high-quality data for clinical trials worldwide.
C-Path is a nonprofit, public-private partnership with the Food and Drug Administration (FDA) and is dedicated to bringing scientists from the FDA, industry and academia together to improve the drug development and regulatory process for medical products. Created in 2011, C-Path established the ePRO Consortium in cooperation with firms that provide technologies and services for capturing patient-reported outcome (PRO) endpoints.
“We look forward to the new relationships and opportunities our membership in the ePRO Consortium will create for our team and our industry,” said Barrett.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
